A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)

Inclusion Criteria:

- Histologically confirmed, locally advanced, not amenable to curative therapy, or
metastatic NSCLC

- ALK-rearrangement confirmed by the Food and Drug Administration (FDA) approved test

- NSCLC that has failed crizotinib treatment

- Measurable disease as defined by RECIST v1.1

- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to
(<=) 2

- Adequate hematologic, hepatic and renal function

Exclusion Criteria:

- Prior therapy with ALK inhibitor other than crizotinib

- Brain or leptomeningeal metastases that are symptomatic and/or requiring treatment

- History of serious cardiac dysfunction

- History of or current active infection with hepatitis B, hepatitis C or human
immunodeficiency virus (HIV)

- Clinically significant gastrointestinal abnormality that would affect absorption of
the drug

- Pregnant or lactating women